Plasma pTau217 Cutoffs for Clinical Use
Researchers assess how biological factors influence plasma biomarker interpretation for amyloid detection.
By
Kathryn Wighton
February 4, 2026
Clinical Scorecard: Plasma pTau217 Cutoffs for Clinical Use
At a Glance
Category Detail
Condition Alzheimer's Disease Diagnosis Key Mechanisms Elevated plasma pTau217 levels due to kidney dysfunction and anemia affect diagnostic accuracy. Target Population Patients with cognitive impairment, including mild cognitive impairment and dementia of Alzheimer type. Care Setting Multicenter clinical evaluations with PET imaging.
Key Highlights
Subgroup-specific plasma pTau217 cutoffs improve diagnostic accuracy. Double-cutoff strategy yields intermediate results in 39% of cases. Optimal cutoffs enhance cost efficiency in chronic kidney disease and anemia. Guideline-Based Recommendations
Diagnosis
Utilize subgroup-specific optimal cutoffs adjusted for kidney function, BMI, and anemia. Management
Consider confirmatory imaging for intermediate results from double-cutoff strategy. Monitoring & Follow-up
Regular assessment of plasma pTau217 levels in patients with kidney dysfunction and anemia. Risks
Increased false classifications without adjusted cutoffs, leading to unnecessary costs. Patient & Prescribing Data
Cognitively unimpaired individuals, patients with mild cognitive impairment, and patients with dementia.
Adjust diagnostic thresholds for plasma pTau217 based on kidney function and anemia status.
Clinical Best Practices
Implement biologically informed approaches for plasma pTau217 testing. Conduct external validation in diverse populations to enhance generalizability. References
